Myoinositol improves sperm parameters and serum reproductive hormones in patients with idiopathic infertility: a prospective double-blind randomized placebo-controlled study
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Male infertility is a multifactorial disorder that affects a significant percentage of couples. Its etiology and pathogenesis remain elusive in about one-third of the cases; this is referred to as idiopathic infertility. Inositols mediate the sperm processes involved into oocyte fertilization, such as penetration of the ovum cumulus oophorus, binding with the zona pellucida and the acrosome reaction. The aim of this double-blind, randomized, placebo-controlled trial was to evaluate the efficacy and safety of myoinositol (the most abundant form of inositols present in nature) treatment in men with idiopathic infertility. To accomplish this, we evaluated the effects of myoinositol on sperm parameters and reproductive hormones at baseline and after 3 months of treatment in men with idiopathic infertility. No adverse reaction was observed. Myoinositol significantly increased the percentage of acrosome-reacted spermatozoa, sperm concentration, and total count and progressive motility compared to placebo. In addition, myoinositol rebalanced serum luteinizing hormone, follicle-stimulating hormone, and inhibin B concentrations. The clinical improvement of idiopathic infertile patients should encourage myoinositol use for the treatment of this disorder, even though its detailed mechanisms at the testicular level remain still unclear.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome
Iuorno, M. J., Jakubowicz, D. J., Baillargeon, J.-P., Dillon, P., Gunn, R. D., Allan, G., & Nestler, J. E. (2002) · Endocrine Practice · doi:10.4158/ep.8.6.417 · Cited by 188 · cited 1×
“…suggest that MI, acting as second messenger, regulates the activities of hormones such as FSH, becoming useful in contrasting the syndromes in which this hormone is quantitatively altered, such as polycystic ovary syndrome (Iuorno et al., 2002; Papaleo et al., 2007, 2009; Dinicola et al., 2014).”
Background
Cited by
Antioxidants for male subfertility
Smits, R. M., Mackenzie-Proctor, R., Yazdani, A., Stankiewicz, M. T., Jordan, V., & Showell, M. G. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007411.pub4 · Cited by 277
Inositols: From Established Knowledge to Novel Approaches
Dinicola, S., Unfer, V., Facchinetti, F., Soulage, C. O., Greene, N. D., Bizzarri, M., Laganà, A. S., Chan, S.-Y., Bevilacqua, A., Pkhaladze, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910575 · Cited by 154
“Besides improving semen characteristics, myo-Ins administration also rebalanced the levels of key reproductive hormones, such as LH, FSH and Inhibin-B [120].”
BackgroundFacchinetti, F., Appetecchia, M., Aragona, C., Bevilacqua, A., Bezerra Espinola, M. S., Bizzarri, M., D’Anna, R., Dewailly, D., Diamanti-Kandarakis, E., Hernández Marín, I., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1737675 · Cited by 63
Metadata
- Authors
- Calogero, A. E., Gullo, G., La Vignera, S., Condorelli, R. A., & Vaiarelli, A.
- Venue
- Andrology
- Publisher
- Wiley
- Published
- 2015-04-09
- Volume
- 3
- Issue
- 3
- Pages
- 491-495
- ISSN
- 2047-2919 (ISSN-L)
- OpenAlex
- W2035871628
- Cited by
- 81
- References
- 1
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.